

# CLINICAL TRIAL

**SOLSTICE - NCT03584165**



Research

## A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study

Rare Eye Disease concerned by the trial :  
Choroideremia

Status of the trial : active, recruiting

Orphan drug recognition : Yes

Inclusion criteria : Subjects are willing and able to give informed consent for participation in the study, and have received a sub-retinal injection of AAV2-REP1 for CHM in an antecedent study.

Exclusion criteria : There are no exclusion criteria for this study.



Inclusion opening date : 01/01/2017



Inclusion closing date (previsional) : 31/12/2018

Children



Adults



### Within ERN-EYE members



Principal location of the trial :

**Center for Ophthalmic Research, University Hospital of Tübingen**  
Elfriede-Aulhorn-Str. 7  
72076 Tübingen  
Germany

[Contact details](#)



Principal investigator name :


Prof. Dr. Dr. Dominik Fischer



Other investigators :

Prof. Dr. med. Karl Ulrich Bartz-Schmidt

**University Hospital of Tübingen**  
Tübingen, Germany



Funder type : Drug company - Industry

[More informations](#)